New Hope for Patients with Rare Cancer
A kidney cancer medication might have found its true calling: fighting thymic cancer.
Which Rx is Better for Advanced Kidney Cancer?
Along with the effectiveness of a cancer medication, physicians and patients want to know about its side effects. What’s the quality of a patient’s life while taking the medicine? Two kidney cancer medications are effective at treating cancer, but have markedly different side effect profiles.
Towards New Treatments for Infant Cancer
Babies can be born with cancer that developed in the mother’s womb. One such cancer is a disease with a long name: infantile myofibromatosis (IM).
FDA Approves New GIST Rx
The US Food and Drug Administration has approved a medication to treat gastrointestinal stromal tumors (GIST) that can’t be removed with surgery, have spread or no longer respond to existing therapies.
Maybe in Animals But Not in Humans
Cancer research usually begins by performing tests on cells. The next step involves animals, and finally humans. A recent controversy involving one medicine’s effect in animals has been refuted in human studies.
Kidney Cancer Drug Updates
At an international oncology meeting, new data has been presented on drugs that treat kidney cancer. The results have been released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Kidney Cancer Rx Approved in Europe
Kidney cancer doesn’t usually have any warning signs until it has become pretty serious. In fact, about a third of patients are diagnosed with an advanced stage of the disease. A medication has been approved in Europe to treat kidney cancer that has spread.
New Path to Fight Acute Myeloid Leukemia
Leukemia is a disease of the blood cells. Acute myeloid leukemia (AML) is seen as an explosion of cancer cells in the bone marrow.
Pfizer Reports Results From Torisel Study
Pfizer Inc announced today that the Phase 3 INTORSECT ( B1771003 ) study, evaluating TORISEL ( temsirolimus ) in patients with advanced renal cell carcinoma ( RCC ) whose disease had progressed on or after SUTENT ( sunitinib malate ) therapy, did not meet the primary endpoint of prolonging progression free survival ( PFS ) when compared to sorafenib .